Revolution Medicines, Inc. officer Jack Lee Anders filed a Form 144 notice on November 12, 2026, proposing the sale of 35,750 shares of common stock acquired through stock option exercise on November 11, 2026.

Key Highlights

  • Proposed sale: 35,750 shares of Revolution Medicines common stock with an aggregate market value of $6,901,895.00, according to the filing.
  • Acquisition method: The shares were acquired on November 11, 2026 via exercise of stock options from the issuer, with cash payment on the same date.
  • Shares outstanding: The filing lists 216,292,323 shares of common stock outstanding at the time of notice.
  • Prior sales: Anders sold 4,053 shares of common stock on September 16, 2026 for gross proceeds of $807,513.37, as disclosed in the three-month sales history.
  • Trading plan: The filing indicates a Rule 10b5-1 plan adoption date of August 12, 2026.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker for the proposed sale.

Anders Option Exercise and Proposed Share Sale at Revolution Medicines

Jack Lee Anders, identified in the filing as an officer of Revolution Medicines, Inc. (NASDAQ:RVMD), submitted a Form 144 notice disclosing a proposed sale of 35,750 shares of the company's common stock. The notice was dated November 11, 2026 and filed with the SEC on November 12, 2026. According to the filing's remarks section, the sale was executed on November 11, 2026, but the Form 144 was filed a day later because "the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday."

The shares proposed for sale were acquired on November 11, 2026 through the exercise of stock options granted by the issuer, with payment made in cash on the same date. The aggregate market value of the 35,750 shares is listed as $6,901,895.00 in the filing. The approximate date of sale is noted as November 11, 2026, and Morgan Stanley Smith Barney LLC Executive Financial Services is identified as the executing broker.

The filing also discloses that Anders sold 4,053 shares of Revolution Medicines common stock on September 16, 2026, generating gross proceeds of $807,513.37, which falls within the required three-month prior sales disclosure window. Anders indicated reliance on a Rule 10b5-1 written trading plan, with a plan adoption date of August 12, 2026. Revolution Medicines is headquartered at 700 Saginaw Drive, Redwood City, California 94063, and the SEC file number listed is 001-39219.

What Was Disclosed

Officer Jack Lee Anders filed a Form 144 notice proposing to sell 35,750 shares of Revolution Medicines common stock, acquired via stock option exercise on November 11, 2026, with an aggregate market value of $6,901,895.00, under a Rule 10b5-1 plan adopted August 12, 2026.